1. Introduction {#sec1}
===============

Drug discovery and development for Alzheimer\'s disease (AD) is arduous. There have been no new drugs approved since 2003, and there are no approved disease-modifying treatments (DMTs) for AD. The challenges of drug development have become more complex as potential trial populations have expanded to include preclinical and prodromal AD, as well as AD dementia [@bib1], [@bib2], [@bib3]. The US Food and Drug Administration (FDA) has provided guidance for clinical trials in AD dementia and predementia AD including use of a single primary outcome in trials of prodromal AD, the role of biomarkers in staging preclinical and prodromal AD, and the use of Bayesian statistics and adaptive clinical trial designs [@bib4], [@bib5], [@bib6]. A new research framework for the diagnosis of AD based on amyloid, tau, and neurodegeneration (ATN) biomarkers was introduced by the National Institute on Aging (NIA) and the Alzheimer\'s Association [@bib7]. This framework allows more precise classification of stages of AD, especially predementia stages, and may facilitate clinical trials of DMTs in AD [@bib8]. Progress in biomarkers relevant to clinical trials of AD include increased understanding of the role of tau positron emission tomography (PET) in characterizing and staging AD and development of new fluid biomarkers such as neurofilament light and neurogranin that are increasingly integrated into clinical trials [@bib9], [@bib10]. These advances comprise the foundations for progress in drug development and demonstrate collaboration among key stakeholders including basic and translational neuroscientists, clinician-scientists, pharmacy benefit managers, regulators, the National Institutes of Health (NIH), advocacy groups, and participants and family members.

In our annual update on the state of the AD drug development pipeline, we build on prior contributions to discuss the current phase 1, phase 2, and phase 3 clinical trials in AD [@bib11], [@bib12], [@bib13]. We describe clinical trials and experimental treatments for disease modification, cognitive enhancement, and neuropsychiatric symptoms of AD. We note changes from 2018 and discuss specific areas of interest including repurposed agents, immunotherapies, novel mechanisms, the use of biomarkers in drug development, and new trends in AD clinical trials. Our goal is to continuously learn from the drug development process, identify best practices, and provide an update and overview of the current state.

2. Methods {#sec2}
==========

[Clinicaltrials.gov](http://Clinicaltrials.gov){#intref0015} provides the source of information for this review. There are other clinical trial registries, and our review does not represent an exhaustive listing of every clinical trial in AD. However, the "Common Rule" governing [clinicaltrials.gov](http://clinicaltrials.gov){#intref0020} mandates registration of all trials from sponsors with an investigational new drug or investigational new device [@bib14], [@bib15] being assessed in the US. Compliance with the required trial registration is high [@bib16], [@bib17], [@bib18]. The US has more clinical trials than any other nation, and thus [clinicaltrials.gov](http://clinicaltrials.gov){#intref0025} includes most agents currently in clinical trials for AD.

We assayed [clinicaltrials.gov](http://clinicaltrials.gov){#intref0030} as of February 12, 2019, and the tables and discussion provided apply to the information available at that time. We comment on terminated trials if the information has become publicly available but is not yet reflected on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0035}. We include all trials of all agents in phase 1, 2, and 3; if trials are presented as 1/2 or 2/3 in the [clinicaltrials.gov](http://clinicaltrials.gov){#intref0040} database, we use that nomenclature in the review. Our trial database tracks trial title; trial number in [clinicaltrials.gov](http://clinicaltrials.gov){#intref0045}; beginning date; projected end date; calculated trial duration; duration of treatment exposure; number of subjects planned for enrollment; number of arms of the study (usually a placebo arm and one or more treatment arms with different doses); whether a biomarker was described; subject characteristics; and sponsorship (a biopharmaceutical company, NIH, academic medical center, "other" entity such as a consortium or a philanthropic organization or a combination of these sponsors). We used the [clinicaltrials.gov](http://clinicaltrials.gov){#intref0050} labeling and included trials that were recruiting, active but not recruiting (e.g., trials that have completed recruiting and are continuing with the exposure portion of the trial), enrolling by invitation, and not yet recruiting. We did not include trials listed as completed, terminated, suspended, unknown, or withdrawn. Information on these trials and reasons for their current status may not be publicly revealed. We do not include trials of nonpharmacologic therapeutic approaches such as cognitive therapies and caregiver interventions; we do not include studies of supplements and medical foods. We provide a table and brief discussion of new device trials (not included in [Fig. 1](#fig1){ref-type="fig"}). We do not include trials of biomarkers, although we note whether biomarkers were used in the trials reviewed. We include stem cell therapies among the interventions reviewed (not integrated into [Fig. 1](#fig1){ref-type="fig"}).Fig. 1All compounds in AD clinical trials as of February 12, 2019 (the inner ring shows phase 3 agents; the middle ring is comprised of phase 2 agents; the outer ring presents phase 1 compounds; agents in green areas are biologics; agents in purple areas are disease-modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial; the icon color shows the class of target for the agent.). Bolded names represent agents new to that phase since 2018.

Drug targets and mechanisms of action (MOA) are important aspects of this review. MOA was determined from the information on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0055} or from a comprehensive search of the literature. In a few cases, the mechanism is undisclosed and could not be identified in the literature; we note these agents as having an "unknown" or "undisclosed" MOA. We grouped the mechanisms into symptomatic agents or DMTs. We divided the symptomatic agents into those that are putative cognitive enhancing agents or those that address neuropsychiatric and behavioral symptoms. DMTs were divided into small molecules or biologics including immunotherapies. DMTs were further divided into those targeting amyloid-related mechanisms, those that have tau-related MOAs, and those with "other" mechanisms such as neuroprotection, anti-inflammatory effects, growth factor promotion, or metabolic effects. The distinction between symptomatic and disease-modifying agents can be arbitrary, and some agents may have both properties. For purposes of this review, we chose what appears to be the principal MOA.

3. Results {#sec3}
==========

3.1. Overview {#sec3.1}
-------------

As of February 12, 2019, there were 132 agents in 156 trials of anti-AD therapies. [Fig. 1](#fig1){ref-type="fig"} shows the universe of pharmacologic compounds currently in clinical trials for AD. Nineteen (14%) agents in trials target cognitive enhancement, and 14 (11%) are intended to treat neuropsychiatric and behavioral symptoms. There are 96 (73%) agents that intend to achieve disease modification; 38 (40%) of these have amyloid; and 17 (18%) have tau as the primary target or as one of several effects seen in nonclinical studies. Eighteen of the antiamyloid agents are small molecules, and 20 are monoclonal antibodies or biological therapies. Anti-tau agents include seven small molecules and ten biologics.

All compounds in AD clinical trials as of February 12, 2019 (the inner ring shows phase 3 agents; the middle ring is comprised of phase 2 agents; the outer ring presents phase 1 compounds; agents in green areas are biologics; agents in purple areas are disease-modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial; the icon color shows the class of target for the agent.). Bolded names represent agents new to that phase since 2018.

3.2. Phase 3 {#sec3.2}
------------

In phase 3, there are 28 agents in 42 trials ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). There are 11 symptomatic agents in phase 3; three cognitive enhancers and eight targeting behavioral symptoms. There are six biological therapies and 11 oral agents/small molecules in phase 3 that target disease modification. All the biological therapies and four of the small molecules have amyloid as the primary or one of several targets. There is one anti-tau agent in phase 3: LMTX (TRx0237). A phase 3 trial of this agent failed to show a drug-placebo difference [@bib19], and based on the results, a new phase 2/3 trial (LUCIDITY) was started in 2018 with a lower dose of LMTX as monotherapy. Other mechanisms represented among phase 3 DMT molecules include neuroprotection, anti-inflammatory approaches, and metabolic interventions. Of the DMTs, two are repurposed agents approved for use in another indication (losartan plus amlodipine plus atorvastatin; and levetiracetam). Of the drugs with amyloid targets, there were six biologics, two beta-site amyloid precursor protein cleavage enzyme (BACE) inhibitors, and one anti-aggregation agent. [Fig. 2](#fig2){ref-type="fig"} shows the MOAs of agents in phase 3.Fig. 2Mechanisms of action of agents in phase 3.Table 1Agents currently in phase 3 of Alzheimer\'s disease drug development (as of February 12, 2019)AgentAgent mechanism classMechanism of actionTherapeutic purposeClinicalTrials.gov IDStatusSponsorStart dateEstimated end dateAducanumab[∗](#tbl1fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibody directed at plaque and oligomersRemove amyloid (DMT)[NCT02484547](NCT02484547){#intref0080}Active, not recruitingBiogenSep 2015Apr 2022[NCT02477800](NCT02477800){#intref0085}Active, not recruitingBiogenAug 2015Apr 2022**AGB101** (low-dose levetiracetam)NeuroprotectiveSV2A modulatorDecrease amyloid-induced neuronal hyperactivity (DMT)[NCT03486938](NCT03486938){#intref0090}RecruitingAgeneBio, NIAJan 2019Nov 2022Plasma exchange with albumin + immunoglobulin[∗](#tbl1fnlowast){ref-type="table-fn"}AntiamyloidPlasma exchangeRemove amyloid (DMT)[NCT01561053](NCT01561053){#intref0095}[†](#tbl1fndagger){ref-type="table-fn"}Active, not recruitingGrifolsMar 2012Dec 2017ALZT-OP1a + ALZT-OP1b (cromolyn + ibuprofen)Antiamyloid, anti-inflammatoryMast cell stabilizer (cromolyn), anti-inflammatory (ibuprofen)Reduce neuronal damage; mast cells may also play a role in amyloid pathology (DMT)[NCT02547818](NCT02547818){#intref0100}RecruitingAZTherapies, Pharma Consulting Group, KCAS Bio, APCER Life SciencesSep 2015Nov 2019**ANAVEX2-73**Anti-tau, antiamyloid, anti-inflammatorySigma-1 receptor agonist (high affinity), muscarinic agonist (low affinity), GSK-3β inhibitorImprove cell signaling (cognitive enhancer) and reduce tau phosphorylation and amyloid (DMT)[NCT03790709](NCT03790709){#intref0105}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingAnavex Life SciencesJul 2018Mar 2021AVP-786Neurotransmitter basedSigma-1 receptor agonist; NMDA receptor antagonistImprove neuropsychiatric symptoms (agitation)[NCT02442765](NCT02442765){#intref0110}Active, not recruitingAvanirSep 2015Apr 2019[NCT02442778](NCT02442778){#intref0115}RecruitingAvanirSep 2015Dec 2019[NCT02446132](NCT02446132){#intref0120}Recruiting, extensionAvanirDec 2015Jun 2022[NCT03393520](NCT03393520){#intref0125}RecruitingAvanirOct 2017Jun 2021AXS-05Neurotransmitter basedSigma-1 receptor agonist; NMDA receptor antagonist (dextromethorphan); dopamine-norepinephrine reuptake inhibitor (bupropion)Improve neuropsychiatric symptoms (agitation)[NCT03226522](NCT03226522){#intref0130}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingAxsome TherapeuticsJul 2017Sep 2019**BHV4157** (troriluzole)NeuroprotectiveGlutamate modulatorReduce synaptic levels of glutamate (DMT)[NCT03605667](NCT03605667){#intref0135}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingBiohaven Pharma, ADCSJul 2018Feb 2020**Brexpiprazole**Neurotransmitter basedAtypical antipsychotic; D2 receptor partial agonist and serotonin-dopamine modulatorImprove neuropsychiatric symptoms (agitation)[NCT03620981](NCT03620981){#intref0140}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingOtsukaAug 2018Nov 2021[NCT03594123](NCT03594123){#intref0145}Recruiting, extensionOtsukaOct 2018Aug 2021[NCT03548584](NCT03548584){#intref0150}RecruitingOtsukaMay 2018Dec 2020[NCT03724942](NCT03724942){#intref0155}Recruiting, extensionOtsukaNov 2018May 2021CAD106 & CNP520AntiamyloidAmyloid vaccine (CAD106), BACE inhibitor (CNP520)Remove amyloid (vaccine); prevent amyloid production (BACE inhibitor) (DMT)[NCT02565511](NCT02565511){#intref0160}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingNovartis, Amgen, NIA,\
Alzheimer\'s Association, Banner Alzheimer\'s InstituteFeb 2016Jan 2025CNP520AntiamyloidBACE inhibitorPrevent amyloid production (DMT)[NCT03131453](NCT03131453){#intref0165}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingNovartis, Amgen, Banner Alzheimer\'s InstituteAug 2017Mar 2025**COR388**Anti-inflammatoryBacterial protease inhibitor targeting a periodontal pathogenReduce neuroinflammation and hippocampal degeneration (DMT)[NCT03823404](NCT03823404){#intref0170}[†](#tbl1fndagger){ref-type="table-fn"}Not yet recruitingCortexymeApr 2019Dec 2022Crenezumab[∗](#tbl1fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibody directed at oligomersRemove amyloid (DMT)[NCT02670083](NCT02670083){#intref0175}Active, not recruitingRocheMar 2016Jul 2021[NCT03114657](NCT03114657){#intref0180}RecruitingRocheMar 2017Oct 2022[NCT03491150](NCT03491150){#intref0185}Recruiting, extensionRocheApr 2018Nov 2022E2609 (elenbecestat)AntiamyloidBACE inhibitorReduce amyloid production (DMT)[NCT02956486](NCT02956486){#intref0190}RecruitingEisai, BiogenOct 2016Jun 2021[NCT03036280](NCT03036280){#intref0195}RecruitingEisai, BiogenDec 2016Jun 2021EscitalopramNeurotransmitter basedSerotonin reuptake inhibitionImprove neuropsychiatric symptoms (agitation)[NCT03108846](NCT03108846){#intref0200}RecruitingNIA, JHSPH Center for Clinical TrialsJan 2018Aug 2022GantenerumabAntiamyloidMonoclonal antibodyRemove amyloid (DMT)[NCT02051608](NCT02051608){#intref0205}Active, not recruitingRocheMar 2014Nov 2020[NCT01224106](NCT01224106){#intref0210}Active, not recruitingRocheNov 2010Aug 2020[NCT03444870](NCT03444870){#intref0215}RecruitingRocheJun 2018May 2023[NCT03443973](NCT03443973){#intref0220}RecruitingRocheJun 2018May 2023Gantenerumab & SolanezumabAntiamyloidMonoclonal antibody directed at plaque and oligomers (gantenerumab); Monoclonal antibody directed at monomers (solanezumab)Remove amyloid/reduce amyloid production (DMT)[NCT01760005](NCT01760005){#intref0225}[†](#tbl1fndagger){ref-type="table-fn"}Active, not recruitingWashington University, Eli Lilly, Roche, NIA, Alzheimer\'s AssociationDec 2012Dec 2023Ginkgo BilobaMetabolicPlant extract with antioxidant propertiesImprove brain blood flow and mitochondrial function (cognitive enhancer)[NCT03090516](NCT03090516){#intref0230}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingNanjing Medical UniversityAug 2016Mar 2018**Guanfacine**Neurotransmitter basedAlpha-2 adrenergic agonistModulation of noradrenergic deficit (cognitive enhancer)[NCT03116126](NCT03116126){#intref0235}Not yet recruitingImperial College London, UK National Institute of Health ResearchSep 2018Sep 2019Icosapent ethyl (IPE)NeuroprotectivePurified form of the omega-3 fatty acid EPAProtect neurons from disease pathology (DMT)[NCT02719327](NCT02719327){#intref0240}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingVA Office of Research and Development, University of Wisconsin, MadisonJun 2017Nov 2021Losartan & Amlodipine & Atorvastatin + exerciseAnti-inflammatory, metabolicAngiotensin II receptor blocker (losartan), calcium channel blocker (amlodipine), cholesterol agent (atorvastatin)Intensive vascular risk reduction can preserve cognitive function (DMT)[NCT02913664](NCT02913664){#intref0245}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingUniversity of Texas SouthwesternSep 2016Sep 2022MasitinibAnti-inflammatorySelective tyrosine kinase inhibitorActivity on mast cells, modulation of inflammatory processes (DMT)[NCT01872598](NCT01872598){#intref0250}Active, not recruitingAB ScienceJan 2012Oct 2019MethylphenidateNeurotransmitter basedDopamine reuptake inhibitorImprove neuropsychiatric symptoms (apathy)[NCT02346201](NCT02346201){#intref0255}RecruitingJohns Hopkins, NIAJan 2016Aug 2020MirtazapineNeurotransmitter basedAlpha-1 antagonistImprove neuropsychiatric symptoms (agitation)[NCT03031184](NCT03031184){#intref0260}RecruitingUniversity of SussexJan 2017Jul 2020Nabilone[∗](#tbl1fnlowast){ref-type="table-fn"}Neurotransmitter basedCannabinoid (receptor agent)Improve neuropsychiatric symptoms (agitation)[NCT02351882](NCT02351882){#intref0265}[†](#tbl1fndagger){ref-type="table-fn"}Active, not recruitingSunnybrook Health Sciences CenterJan 2015Mar 2019Octohydroaminoacridine SuccinateNeurotransmitter basedAcetylcholinesterase inhibitorImprove acetylcholine signaling (cognitive enhancer)[NCT03283059](NCT03283059){#intref0270}RecruitingShanghai Mental Health Center, Changchun-Huayang High-tech Co., Jiangsu Sheneryang High-tech Co.Aug 2017Feb 2020SolanezumabAntiamyloidMonoclonal antibody directed at monomersRemove amyloid and prevent aggregation (DMT)[NCT02008357](NCT02008357){#intref0275}Active, not recruitingEli Lilly, ATRIFeb 2014Jul 2022TRx0237 (LMTX)Anti-tauTau protein aggregation inhibitorReduce tau-mediated neuronal damage (DMT)[NCT03446001](NCT03446001){#intref0280}[†](#tbl1fndagger){ref-type="table-fn"}RecruitingTauRx TherapeuticsJan 2018Jun 2020ZolpidemNeurotransmitter basedPositive allosteric modulator of GABA-A receptorsImprove neuropsychiatric symptoms (sleep disorders)[NCT03075241](NCT03075241){#intref0285}RecruitingBrasilia University HospitalOct 2016Dec 2018[^1][^2][^3][^4][^5]

There were six prevention trials enrolling cognitively normal participants; 14 trials in patients with prodromal AD/mild cognitive impairment (MCI) or prodromal-to-mild AD; 12 trials of patients with mild-to-moderate AD; and 10 trials of patients with mild-to-severe AD.

Phase 3 trials included an average of 640 participants and had a mean duration of 246 weeks (including the recruitment and the treatment period). Mean treatment exposure period was 73 weeks. DMT trials were longer and larger than trials of symptomatic agents with a mean duration of 297 weeks including 112 treatment weeks, and included an average of 862 participants. The mean duration of cognitive enhancer trials was 88 weeks (17 treatment weeks), and they included an average of 333 participants. Trials of agents for behavioral symptoms had a mean duration of 187 weeks (15 treatment weeks) and included a mean of 311 subjects.

The average duration of treatment exposure for phase 3 DMTs is 112 weeks, and the mean period from trial initiation to primary completion date (final data collection date for primary outcome measures) is 269 weeks. This indicates that 157 weeks, more than the treatment period, is the average anticipated recruitment time. When examined by trial population, DMT prevention trials are 405 weeks in duration (192 treatment weeks); trials for patients with MCI/prodromal/prodromal-to-mild AD are 263 weeks in duration (98 treatment weeks); and trials for patients with mild-to-moderate AD are 264 weeks in duration (57 treatment weeks). Planned recruitment periods for these three types of trials are 192, 130, and 191 weeks, respectively.

3.3. Phase 2 {#sec3.3}
------------

Phase 2 has a larger array of therapies and mechanisms that are being assessed than are represented in phase 3. There are 74 agents in 83 trials ([Figs. 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). Of these, there are 20 symptomatic agents; 14 cognitive enhancers; and six agents targeting behavioral symptoms. There are 53 potential disease-modifying agents in phase 2 trials; 16 biologics and 37 small molecules. One agent had an undisclosed mechanism. Twelve of the small molecules and eight of the biologics have amyloid reduction as one of the mechanisms observed in nonclinical studies (38% of DMTs). Four small molecules and six biologics in phase 2 target tau as one of their mechanisms (19% of DMTs). There are 24 small molecules and two biologics with neuroprotection as one of the mechanisms (49% of DMTs). Other mechanisms represented in phase 2 include anti-inflammatory and metabolic interventions as the primary or one of a combination of effects documented in animal models. There are six trials involving stem cell therapies. Sixteen of the DMT agents are repurposed agents approved for use in another indication.Fig. 3Mechanisms of action of agents in phase 2.Table 2Agents currently in phase 2 of Alzheimer\'s disease drug development (as of February 12, 2019)AgentAgent mechanism classMechanism of actionTherapeutic purposeClinicalTrials.gov IDStatusSponsorStart dateEstimated end dateAADvac1Anti-tauActive immunotherapyRemove tau and prevent tau propagation (DMT)[NCT02579252](NCT02579252){#intref0295}Active, not recruitingAxon NeuroscienceMar 2016Jun 2019ABBV-8E12Anti-tauMonoclonal antibodyRemove tau and prevent tau propagation (DMT)[NCT02880956](NCT02880956){#intref0300}RecruitingAbbVieOct 2016Sep 2022[NCT03712787](NCT03712787){#intref0305}Not yet recruiting, extensionAbbVieNov 2018Aug 2027**ABvac40**AntiamyloidActive immunotherapyRemove amyloid (DMT)[NCT03461276](NCT03461276){#intref0310}RecruitingAraclon BiotechFeb 2018Feb 2021**AD-35**Neurotransmitter basedAcetylcholinesterase inhibitorImprove acetylcholine signaling (cognitive enhancer)[NCT03625401](NCT03625401){#intref0315}RecruitingZhejiang Hisun Pharmaceutical, Medpace, Inc.Oct 2018Jul 2020[NCT03790982](NCT03790982){#intref0320}Active, not recruitingZhejiang Hisun PharmaceuticalDec 2018Jul 2021Aducanumab[∗](#tbl2fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibody directed at plaque and oligomersRemove amyloid (DMT)[NCT03639987](NCT03639987){#intref0325}RecruitingBiogenDec 2018Nov 2023**AMX0035**NeuroprotectiveBlocks mitochondrial and endoplasmic reticulum stressBlocks nerve cell death and neuroinflammation (DMT)[NCT03533257](NCT03533257){#intref0330}RecruitingAmylyx Pharmaceuticals, ADDF, Alzheimer\'s AssociationAug 2018Sep 2020ANAVEX 2-73Anti-tau, antiamyloid, anti-inflammatorySigma-1 receptor agonist (high affinity); muscarinic agonist (low affinity); GSK-3β inhibitorImprove cell signaling (cognitive enhancer) and reduce tau phosphorylation and amyloid (DMT)[NCT02756858](NCT02756858){#intref0335}Active, not recruiting, extensionAnavex Life SciencesMar 2016Nov 2020**APH-1105**AntiamyloidAlpha-secretase modulatorReduce amyloid (DMT)[NCT03806478](NCT03806478){#intref0340}Not yet recruitingAphiosJun 2021Dec 2022**AR1001**AntiamyloidPDE 5 inhibitorImprove synaptic plasticity and reduce amyloid (DMT)[NCT03625622](NCT03625622){#intref0345}RecruitingAriBio Co.Jan 2019Aug 2020AstroStemRegenerativeStem cell therapy; autologous adipose tissue derived mesenchymal stem cellsRegenerate neurons (DMT)[NCT03117738](NCT03117738){#intref0350}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingNature Cell Co.Apr 2017Jul 2019BACUndisclosedUndisclosedUndisclosed[NCT02886494](NCT02886494){#intref0355}RecruitingCharsire BiotechnologyDec 2016Nov 2019[NCT02467413](NCT02467413){#intref0360}Not yet recruitingCharsire Biotechnology,\
A2 Healthcare Taiwan CorporationDec 2019Dec 2021BenfotiamineMetabolicSynthetic thiamine (B1)Improve multiple cellular processes (cognitive enhancer)[NCT02292238](NCT02292238){#intref0365}RecruitingBurke Medical Research Institute, Columbia University, NIA, ADDFNov 2014Nov 2019BI425809Neurotransmitter basedGlycine transporter 1 inhibitorFacilitate NMDA receptor activity (cognitive enhancer)[NCT02788513](NCT02788513){#intref0370}RecruitingBoehringer IngelheimAug 2016Mar 2020BIIB092Anti-tauMonoclonal antibodyRemove tau and reduce tau propagation (DMT)[NCT03352557](NCT03352557){#intref0375}RecruitingBiogenMay 2018Jul 2021**BPN14770**Anti-inflammatoryPDE4D inhibitorProlongs cAMP activity (cognitive enhancer)[NCT03817684](NCT03817684){#intref0380}Not yet recruitingTetra Discovery PartnersApr 2019Jun 2020ByrostatinMetabolicProtein kinase C modulatorImprove multiple cellular processes (cognitive enhancer)[NCT03560245](NCT03560245){#intref0385}RecruitingNeurotrope BioscienceJun 2018Jul 2019CandesartanNeuroprotective, metabolic, antiamyloidAngiotensin receptor blockerImprove vascular functioning and reduce amyloid (DMT)[NCT02646982](NCT02646982){#intref0390}RecruitingEmory UniversityJun 2016Sep 2021CERE-110[∗](#tbl2fnlowast){ref-type="table-fn"}NeuroprotectiveAdeno-associated virus-based gene delivery vector of nerve growth factorCholinergic neuronal hypertrophy; slows age-related neurodegeneration (DMT)[NCT00876863](NCT00876863){#intref0395}Active, not recruitingSangamo Therapeutics, ADCSSep 2009Mar 2020CilostazolNeuroprotectivePDE-3 inhibitorReduce accumulation of amyloid and reduce tau phosphorylation; improve cerebral circulation (DMT)[NCT02491268](NCT02491268){#intref0400}RecruitingNational Cerebral and Cardiovascular Center, JapanJul 2015Dec 2020Crenezumab[∗](#tbl2fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibody targeting soluble oligomersRemove amyloid (DMT)[NCT01998841](NCT01998841){#intref0405}Active, not recruitingGenentech, NIA\
Banner Alzheimer\'s InstituteDec 2013Feb 2022CT1812AntiamyloidSigma-2 receptor antagonistReduce amyloid-beta protein-induced synaptic toxicity (DMT)[NCT03507790](NCT03507790){#intref0410}RecruitingCognition TherapeuticsOct 2018Dec 2019[NCT03493282](NCT03493282){#intref0415}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingCognition TherapeuticsApr 2018Jan 2020Curcumin + aerobic yogaNeuroprotectiveHerb with antioxidant and anti-inflammatory propertiesReduce amyloid production, decrease neuroglial cell proliferation (DMT)[NCT01811381](NCT01811381){#intref0420}RecruitingVA Office of Research and DevelopmentJan 2014Dec 2019DAOINeurotransmitter basedNMDA receptor modulationEnhance NMDA activity (cognitive enhancer)[NCT03752463](NCT03752463){#intref0425}RecruitingChang Gung Memorial Hospital, TaiwanMay 2015Dec 2019**Dapagliflozin**MetabolicSGLT2 inhibitorImprove insulin sensitivity (cognitive enhancer)[NCT03801642](NCT03801642){#intref0430}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingUniversity of KansasFeb 2019Oct 2020DeferiproneAntiamyloid, neuroprotectiveIron chelating agentReduce reactive oxygen species that damage neurons; effect on amyloid and BACE pathology (DMT)[NCT03234686](NCT03234686){#intref0435}RecruitingNeuroscience Trials AustraliaJan 2018Dec 2021**DHA**NeuroprotectiveOmega-3 fatty acid in high concentration in the brainReduce amyloid production, improve synaptic function (DMT)[NCT03613844](NCT03613844){#intref0440}RecruitingUniversity of Southern CaliforniaJul 2018Sep 2024DHP1401MetabolicAffects cAMP activityImprove synaptic function (cognitive enhancer)[NCT03055741](NCT03055741){#intref0445}Active, not recruitingDaehwa Pharmaceutical Co.Dec 2016Jun 2019DronabinolNeurotransmitter basedCB1 and CB2 endocannabinoid receptor partial agonistImprove neuropsychiatric symptoms (agitation)[NCT02792257](NCT02792257){#intref0450}RecruitingMclean Hospital, Johns Hopkins UniversityMar 2017Dec 2020E2609 (elenbecestat)AntiamyloidBACE inhibitorReduce amyloid production (DMT)[NCT02322021](NCT02322021){#intref0455}Active, not recruitingEisai, BiogenNov 2014Jun 2020Elderberry JuiceAnti-inflammatory, neuroprotectiveAntioxidant rich in anthocyaninsImprove mitochondrial function (DMT)[NCT02414607](NCT02414607){#intref0460}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingUniversity of MissouriSep 2016Apr 2019FormoterolMetabolicBeta-2 adrenergic receptor agonistEffects on multiple cellular pathways (DMT)[NCT02500784](NCT02500784){#intref0465}RecruitingPalo Alto Veterans Institute for Research, Mylan,\
Alzheimer\'s AssociationJan 2015Jul 2018Grapeseed ExtractNeuroprotectivePolyphenolic compounds; antioxidantAnti-oligomerization agent; prevents aggregation of amyloid and tau (DMT)[NCT02033941](NCT02033941){#intref0470}RecruitingMount Sinai School of Medicine, NCCIHNov 2014Sep 2018**GRF6019**Anti-inflammatoryHuman plasma protein fraction infusionsYoung blood parabiosis can counteract inflammatory and age-related processes in the brain (DMT)[NCT03520998](NCT03520998){#intref0475}RecruitingAlkahestApr 2018Nov 2019[NCT03765762](NCT03765762){#intref0480}RecruitingAlkahestDec 2018Nov 2019GV1001Antiamyloid, metabolicTelomerase reverse transcriptase peptide vaccineEffects on multiple cellular pathways including amyloid pathology (DMT)[NCT03184467](NCT03184467){#intref0485}RecruitingGemVax & KaelJun 2017Jun 2019hUCB-MSCsRegenerativeStem cell therapyRegenerate neurons; reduce amyloid plaque deposition and soluble amyloid; decrease microglial systemic inflammation (DMT)[NCT02054208](NCT02054208){#intref0490}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingMedipost Co.Feb 2014Jul 2019[NCT03172117](NCT03172117){#intref0495}[†](#tbl2fndagger){ref-type="table-fn"}Recruiting, extensionMedipost Co.May 2017Dec 2021[NCT02513706](NCT02513706){#intref0500}OngoingSouth China Research CenterOct 2017Oct 2019[NCT02672306](NCT02672306){#intref0505}[†](#tbl2fndagger){ref-type="table-fn"}OngoingSouth China Research CenterOct 2017Oct 2019[NCT02833792](NCT02833792){#intref0510}Active, not recruitingStemedica Cell TechnologiesJun 2016Jun 2020ID1201AntiamyloidAlpha-secretase enhancerReduce amyloid (DMT)[NCT03363269](NCT03363269){#intref0515}OngoingIlDong PharmaceuticalApr 2016Dec 2018Insulin glulisine (intranasal)MetabolicIncrease insulin signaling in the brainEnhance cell signaling and growth; promote neuronal metabolism (DMT)[NCT02503501](NCT02503501){#intref0520}OngoingHealthPartners InstituteAug 2015May 2019IONIS MAPTRx (BIIB080)RNA-based anti-tauMAPT RNA inhibitor; antisense oligonucleotideReduce tau production (DMT)[NCT03186989](NCT03186989){#intref0525}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingIonis Pharmaceuticals, BiogenJun 2017Feb 2020LemborexantNeurotransmitter basedDual antagonist of orexin OX1 and OX2 receptorsImprove neuropsychiatric symptoms (sleep disorders)[NCT03001557](NCT03001557){#intref0530}Active, not recruitingEisai, PurdueDec 2016Apr 2020LevetiracetamNeuroprotectiveSV2A modulatorDecrease amyloid-induced neuronal hyperactivity (DMT)[NCT02002819](NCT02002819){#intref0535}RecruitingUniversity of California, San FranciscoJun 2014Dec 2019[NCT03489044](NCT03489044){#intref0540}RecruitingUniversity of Oxford, NHS Foundation Trust, UCB PharmaNov 2018Jan 2020[NCT03461861](NCT03461861){#intref0545}RecruitingMedical College of Wisconsin, NIANov 2018Mar 2019LiraglutideMetabolicGlucagon-like peptide 1 receptor agonistEnhance cell signaling (cognitive enhancer)[NCT01843075](NCT01843075){#intref0550}RecruitingImperial College LondonJan 2014Mar 2019LithiumNeurotransmitter basedIon channel modulatorImprove neuropsychiatric symptoms (agitation, mania, psychosis)[NCT02129348](NCT02129348){#intref0555}RecruitingNew York State Psychiatric Institute, NIAJun 2014Apr 2019LM11A-31-BHSNeuroprotectivep75 neurotrophin receptor ligandInhibits tau phosphorylation and synaptic dysfunction; prevents amyloid-induced toxicity (DMT)[NCT03069014](NCT03069014){#intref0560}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingPharmatrophiX Inc.,\
NIAFeb 2017Oct 2019**Lupron** (leuprolide acetate depot)MetabolicGonadotropin-releasing hormone receptor agonistSuppresses brain-produced gonadotropin-releasing hormone (cognitive enhancer)[NCT03649724](NCT03649724){#intref0565}Not yet recruitingNew York UniversityDec 2018Dec 2020L-SerineNeuroprotectiveAmino acidStabilizes protein misfolding (DMT)[NCT03062449](NCT03062449){#intref0570}RecruitingDartmouth-Hitchcock Medical Center, Brain Chemistry LaboratoriesMar 2017Aug 2019LY3002813AntiamyloidMonoclonal antibodyRemove amyloid (DMT)[NCT03367403](NCT03367403){#intref0575}RecruitingEli LillyDec 2017Sep 2021**LY3303560**Anti-tauMonoclonal antibodyRemove tau and reduce tau propagation (DMT)[NCT03518073](NCT03518073){#intref0580}RecruitingEli LillyApr 2018Oct 2021Methylene blueAnti-tauTau protein aggregation inhibitorReduce neurofibrillary tangle formation (DMT)[NCT02380573](NCT02380573){#intref0585}Active, not recruitingTexas Alzheimer\'s Research and Care ConsortiumJul 2015Jul 2019MLC901 (NeuroAiD)Neuroprotective, anti-inflammatoryTraditional Chinese medicine consisting of several herbsMultiple cellular pathways (DMT)[NCT03038035](NCT03038035){#intref0590}RecruitingNational University Hospital, SingaporeDec 2016Jun 2019MontelukastAnti-inflammatoryLeukotriene receptor antagonistReduce inflammatory pathways (cognitive enhancer)[NCT03402503](NCT03402503){#intref0595}RecruitingIntelGenx Corp.Nov 2018Oct 2020MP-101Neurotransmitter basedEnhance mitochondrial functioningImprove neuropsychiatric symptoms (psychosis)[NCT03044249](NCT03044249){#intref0600}RecruitingMediti PharmaMay 2017Jan 2021**NA-831** (traneurocin)NeuroprotectiveUndisclosedNeurogenesis and neuroprotection (DMT)[NCT03538522](NCT03538522){#intref0605}Not yet recruitingNeuroActivaSep 2018Apr 2019Neflamapimod (VX-745)Anti-inflammatorySelective p38 MAPK inhibitorAffects multiple cellular processes including inflammation and cellular plasticity; reduces amyloid plaque burden (DMT)[NCT03402659](NCT03402659){#intref0610}RecruitingEIP Pharma, VU UniversityDec 2017Jul 2019[NCT03435861](NCT03435861){#intref0615}RecruitingEIP Pharma, Toulouse University, Foundation Plan AlzheimerOct 2018Jan 2021NicotinamideAnti-tau, neuroprotectiveHistone deacetylase inhibitorReduce tau-induced microtubule depolymerization (DMT)[NCT03061474](NCT03061474){#intref0620}RecruitingUniversity of California, IrvineJul 2017Feb 2019NicotineNeurotransmitter basedNicotinic acetylcholine receptor agonistEnhance acetylcholine signaling (cognitive enhancer)[NCT02720445](NCT02720445){#intref0625}RecruitingUniv. of Southern California, NIA, ATRI, Vanderbilt UniversityJan 2017Dec 2019NilotinibAntiamyloid, anti-tauTyrosine kinase inhibitorReduce amyloid and tau phosphorylation (DMT)[NCT02947893](NCT02947893){#intref0630}Active, not recruitingGeorgetown UniversityJan 2017Dec 2019Octagam 10%Antiamyloid10% human normal immunoglobulinRemove amyloid (DMT)[NCT03319810](NCT03319810){#intref0635}RecruitingSutter HealthJan 2018May 2019Omega-3 PUFANeuroprotectiveFish oil concentrate standardized to long chain in n-3 PUFA contentSupport small blood vessels in the brain (DMT)[NCT01953705](NCT01953705){#intref0640}Active, not recruitingOregon Health and Science University, NIAMay 2014Sep 2019PimavanserinNeurotransmitter based5-HT2A inverse agonistImprove neuropsychiatric symptoms (psychosis)[NCT03118947](NCT03118947){#intref0645}Active, not recruiting, extensionAcadiaFeb 2017Aug 2019PiromelatineNeurotransmitter basedMelatonin receptor agonist; 5-HT 1A and 1D serotonin receptor agonistEnhance cellular signaling (cognitive enhancer)[NCT02615002](NCT02615002){#intref0650}RecruitingNeurim PharmaceuticalsNov 2015Apr 2019PosiphenAntiamyloidSelective inhibitor of APP productionReduce amyloid production (DMT)[NCT02925650](NCT02925650){#intref0655}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingQR Pharma, ADCSMar 2017Dec 2019**Prazosin**Neurotransmitter basedAlpha-1 adrenoreceptor antagonistImprove neuropsychiatric symptoms (agitation)[NCT03710642](NCT03710642){#intref0660}RecruitingADCS, NIAJan 2019Dec 2022**PTI-125**Neuroprotective, anti-inflammatoryFLNA inhibitorReduce amyloid, prevent tau hyperphosphorylation and inflammatory toxicity (DMT)[NCT03748706](NCT03748706){#intref0665}RecruitingPain Therapeutics, NIHNov 2018Mar 2019Rasagiline[∗](#tbl2fnlowast){ref-type="table-fn"}Antiamyloid, neuroprotective, metabolicMonoamine oxidase B inhibitorEnhance mitochondria activity and inactivate reactive oxygen species (cognitive enhancer), also effect on amyloid pathology (DMT)[NCT02359552](NCT02359552){#intref0670}Active, not recruitingThe Cleveland ClinicMay 2015Feb 2019RiluzoleNeuroprotectiveGlutamate receptor antagonistInhibit glutamate neurotransmission (DMT)[NCT01703117](NCT01703117){#intref0675}RecruitingRockefeller UniversityNov 2013Nov 2019RO7105705 (MTAU9937 A)Anti-tauMonoclonal antibodyRemove tau (DMT)[NCT03289143](NCT03289143){#intref0680}RecruitingGenentechOct 2017Sep 2022[NCT03828747](NCT03828747){#intref0685}RecruitingGenentechFeb 2019Sep 2021**RPh201**NeuroprotectiveUndisclosedPromote neurogenesis (DMT)[NCT03462121](NCT03462121){#intref0690}RecruitingRegenera PharmaMar 2018Apr 2019Sargramostim[∗](#tbl2fnlowast){ref-type="table-fn"} (GM-CSF)Antiamyloid, neuroprotectiveSynthetic granulocyte colony stimulatorStimulate innate immune system to remove amyloid pathology; increase neuronal connectivity (DMT)[NCT01409915](NCT01409915){#intref0695}Active, not recruitingUniversity of Colorado, Denver,\
The Dana FoundationMar 2011Nov 2019S-equol (AUS-131)NeuroprotectiveNonhormonal estrogen receptor B agonistMitochondrial function potentiation; improve synaptic functioning, protects neurons (DMT)[NCT03101085](NCT03101085){#intref0700}[†](#tbl2fndagger){ref-type="table-fn"}RecruitingAusio Pharmaceuticals, University of KansasMay 2017Oct 2019SUVN-502Neurotransmitter based5-HT 6 antagonistImprove neuronal signaling (cognitive enhancer)[NCT02580305](NCT02580305){#intref0705}Active, not recruitingSuven Life SciencesSep 2015May 2019Telmisartan & PerindoprilNeuroprotective, anti-inflammatoryAngiotensin II receptor blocker, PPAR-gamma agonist (telmisartan); angiotensin converting enzyme inhibitor (perindopril)Improve vascular functioning (DMT)[NCT02085265](NCT02085265){#intref0710}RecruitingSunnybrook Health Sciences Center,\
ADDFMar 2014Mar 2021**TEP**AntiamyloidAntiemetic; activates transport protein ABCC1Remove amyloid (DMT)[NCT03417986](NCT03417986){#intref0715}RecruitingImmungenetics AGNov 2017Jul 2021UB-311AntiamyloidActive immunotherapyReduce amyloid (DMT)[NCT03531710](NCT03531710){#intref0720}Recruiting, extensionUnited NeuroscienceAug 2018Mar 2021ValacyclovirNeuroprotective, anti-inflammatoryAntiviral agentProtects against HSV-1/2 infection and inflammation (DMT)[NCT02997982](NCT02997982){#intref0725}RecruitingUmea UniversityDec 2016Apr 2019[NCT03282916](NCT03282916){#intref0730}RecruitingNew York State Psychiatric Institue, NIH, NIAFeb 2018Aug 2022Xanamem (UE2343)NeuroprotectiveBlocks 11 beta-HSD1 enzyme activityDecrease cortisol production and neurodegeneration (DMT)[NCT02727699](NCT02727699){#intref0735}Active, not recruitingActinogenMar 2017Jul 2019[^6][^7][^8][^9][^10]

Of the drugs with amyloid targets, there were seven immunotherapies, one colony-stimulating factor, two BACE inhibitors, and two alpha-secretase modulators. Two agents targeted synaptic activity, two were anti-aggregation agents, and two agents involved neuroprotection or a metabolic MOA. There were two agents targeting both amyloid and tau reduction. [Fig. 3](#fig3){ref-type="fig"} shows the MOAs of agents in phase 2.

Three of the phase 2 trials were prevention trials; 36 trials involved patients with prodromal or prodromal and mild AD; 38 were trials for mild-to-moderate AD; two trials were for patients with severe AD; two included patients with mild, moderate, or severe AD; one included patients with MCI or healthy volunteers; and one trial was for prodromal or mild-to-moderate AD.

Phase 2 trials are shorter in duration and smaller in terms of participant number than phase 3 trials; phase 2 trials had a mean duration of 178 weeks, average treatment period of 45 weeks, and included an average of 143 subjects in each trial.

3.4. Phase 1 {#sec3.4}
------------

Phase 1 has 30 agents in 31 trials ([Fig. 1](#fig1){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). There are two cognitive enhancers being assessed in phase 1. There are currently no agents addressing neuropsychiatric symptoms in phase 1. In addition, there are 13 small molecules and 13 biologics being assessed in phase 1. The MOA was not identified for two agents. Two of the small molecules and six of the biologics have amyloid as a primary target or one among several targets. Tau is targeted by one small molecule and four biologics in phase 1 studies. Other mechanisms represented in phase 1 include neuroprotection, metabolic, anti-inflammatory, and regenerative interventions.Table 3Agents currently in phase 1 of Alzheimer\'s disease drug development (as of February 12, 2019)AgentAgent mechanism classMechanism of actionTherapeutic purposeClinicalTrials.gov IDStatusSponsorStart dateEstimated end date**AAVrh.10hAPOE2**NeuroprotectiveSerotype rh. 10 adeno-associated virus gene transfer vector expressing the cDNA coding for human ApoE2Conversion of the ApoE protein isoforms in the CSF of ApoE4 homozygotes from ApoE4 to ApoE2-ApoE4 (DMT)[NCT03634007](NCT03634007){#intref0745}Not yet recruitingCornell UniversityJan 2019Dec 2021Aducanumab[∗](#tbl3fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibodyRemove amyloid (DMT)[NCT01677572](NCT01677572){#intref0750}Active, not recruitingBiogenOct 2012Oct 2021**AL002**Anti-inflammatoryMonoclonal antibody targeting TREM2 receptorsPrevents inflammatory activity (DMT)[NCT03635047](NCT03635047){#intref0755}RecruitingAlectorNov 2018Mar 2020**AL003**Anti-inflammatoryMonoclonal antibody targeting SIGLEC-3Reactivates microglia and immune cells in the brain (DMT)[NCT03822208](NCT03822208){#intref0760}Not yet recruitingAlectorMar 2019Jul 2020Allopregnanolone (Allo-IM)Neuroprotective, metabolicGABA receptor modulatorImprove neurogenesis (DMT)[NCT03748303](NCT03748303){#intref0765}Not yet recruitingUniversity of Southern California, University of Arizona, Alzheimer\'s AssociationDec 2018Dec 2020BDPP (bioactive dietary polyphenol preparation)NeuroprotectiveCombination of grape seed polyphenolic extract and resveratrolPrevents amyloid and tau aggregation (DMT)[NCT02502253](NCT02502253){#intref0770}RecruitingJohns Hopkins University, Mount Sinai School of MedicineJun 2015Oct 2019BIIB076Anti-tauMonoclonal antibodyRemove tau and reduce tau propagation (DMT)[NCT03056729](NCT03056729){#intref0775}RecruitingBiogenFeb 2017Jul 2019**CKD-355**UndisclosedUndisclosedUndisclosed[NCT03802162](NCT03802162){#intref0780}Not yet recruitingChong Kun Dang PharmaceuticalFeb 2019Jul 2019Crenezumab[∗](#tbl3fnlowast){ref-type="table-fn"}AntiamyloidMonoclonal antibody targeting oligomersRemove amyloid (DMT)[NCT02353598](NCT02353598){#intref0785}Active, not recruitingGenentechFeb 2015Sep 2023**CT1812**AntiamyloidSigma-2 receptor antagonistReduce amyloid-beta protein-induced synaptic toxicity (DMT)[NCT03522129](NCT03522129){#intref0790}RecruitingCognition TherapeuticsMay 2018Dec 2019**Dabigatran**NeuroprotectiveDirect thrombin inhibitor; anticoagulantReduce neurovascular damage (DMT)[NCT03752294](NCT03752294){#intref0795}Not yet recruitingUniversity of Rhode Island, ADDF, Boehringer IngelheimNov 2018Dec 2021**DNL747**Neuroprotective, anti-inflammatoryRIPK1 inhibitorReduce cytokines and other inflammatory factors (DMT)[NCT03757325](NCT03757325){#intref0800}RecruitingDenali TherapeuticsFeb 2019Aug 2019**Efavirenz**AntiamyloidAntiretroviral; nonnucleoside reverse transcriptase inhibitorIncrease cholesterol removal and enhance amyloid reduction (DMT)[NCT03706885](NCT03706885){#intref0805}RecruitingCase Western Reserve University, Cleveland Medical Center, Massachusetts General HospitalDec 2018May 2020Escitalopram & VenlafaxineNeurotransmitter basedSSRI, SNRIImprove neurotransmission (cognitive enhancer)[NCT03274817](NCT03274817){#intref0810}RecruitingNew York UniversityJul 2017Jan 2019hMSCs (human mesenchymal stem cells)RegenerativeStem cell therapyRegenerate neurons[NCT02600130](NCT02600130){#intref0815}RecruitingLongeveronAug 2016Mar 2020Insulin aspart (intranasal)MetabolicIncrease insulin signaling in the brainNeuroprotection and enhanced neuronal function; protects against amyloid toxicity (DMT)[NCT02462161](NCT02462161){#intref0820}RecruitingWake Forest School of Medicine, NIA, General ElectricMay 2015Sep 2019**J147**NeuroprotectiveMitochondrial ATP synthase inhibitorProtects neurons from multiple toxicities associated with aging (DMT)[NCT03838185](NCT03838185){#intref0825}RecruitingAbrexaJan 2019Jan 2020JNJ-63733657Anti-tauMonoclonal antibodyRemove tau and reduce tau propagation (DMT)[NCT03375697](NCT03375697){#intref0830}RecruitingJanssenDec 2017Oct 2019Lu AF20513AntiamyloidActive immunotherapyRemove amyloid (DMT)[NCT02388152](NCT02388152){#intref0835}Active, not recruitingLundbeckMar 2015Dec 2019[NCT03668405](NCT03668405){#intref0840}Recruiting, extensionLundbeckJun 2018Nov 2020[NCT03819699](NCT03819699){#intref0845}RecruitingLundbeckDec 2018Jun 2019LY3002813AntiamyloidMonoclonal antibodyRemove amyloid (DMT)[NCT02624778](NCT02624778){#intref0850}Active, not recruitingEli LillyDec 2015May 2020LY3303560Anti-tauMonoclonal antibodyRemove tau and reduce tau propagation (DMT)[NCT03019536](NCT03019536){#intref0855}Active, not recruitingEli LillyJan 2017Jun 2020**LY3372993**AntiamyloidMonoclonal antibodyRemove amyloid (DMT)[NCT03720548](NCT03720548){#intref0860}RecruitingEli LillyNov 2018Sep 2021**MK-4334**UndisclosedUndisclosedUndisclosed[NCT03740178](NCT03740178){#intref0865}Not yet recruitingMerckJan 2019Jun 2019NDX-1017RegenerativeHepatocyte growth factorRegenerate neurons (DMT)[NCT03298672](NCT03298672){#intref0870}RecruitingM3 Biotechnology, ADDF, Biotrial Inc.Oct 2017Apr 2019NPT088Antiamyloid, anti-tauIgG1-Fc-GAIM fusion proteinClear amyloid and tau (DMT)[NCT03008161](NCT03008161){#intref0875}Active, not recruitingProclara Biosciences, Alzheimer\'s AssociationDec 2016Apr 2019SalsalateAnti-inflammatoryNonsteroidal anti-inflammatoryReduce neuronal injury (DMT)[NCT03277573](NCT03277573){#intref0880}RecruitingUniversity of California, San FranciscoJul 2017Oct 2019TelmisartanNeuroprotective, anti-inflammatoryAngiotensin II receptor blocker, PPAR-gamma agonistImprove vascular functioning and effects on amyloid pathology (DMT)[NCT02471833](NCT02471833){#intref0885}RecruitingEmory UniversityApr 2015Apr 2019**THN201**Neurotransmitter basedCholinesterase inhibitor + antimalarial glial cell modulatorImprove acetylcholine signaling and modulate astrocyte function (DMT)[NCT03698695](NCT03698695){#intref0890}RecruitingTheranexusSep 2018Jul 2019TPI-287Anti-tauMicrotubule protein modulatorReduce tau-mediated cellular damage (DMT)[NCT01966666](NCT01966666){#intref0895}Active, not recruitingUniversity of California, San FranciscoNov 2013Mar 2019VorinostatNeuroprotectiveHistone deacetylase inhibitorEnhance multiple cellular processes including tau aggregation and amyloid deposition (DMT)[NCT03056495](NCT03056495){#intref0900}RecruitingGerman Center for Neurodegenerative Diseases, University Hospital, Bonn, University of GottingenSep 2017Oct 2019[^11][^12][^13][^14]

Phase 1 trials had an average duration of 141 weeks (recruitment and treatment period) and included a mean number of 58 participants in each trial.

3.5. Trial sponsors {#sec3.5}
-------------------

Across all trials, 54% are sponsored by the biopharma industry, 35% by Academic Medical Centers (with funding from NIH, industry, or other entities), and 10% by others. [Table 4](#tbl4){ref-type="table"} shows the sponsor of agents in each phase of development.Table 4Trial sponsor for each phase of development ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0910} as of February 12, 2019)SponsorN of trials (%)Phase 1Phase 2Phase 3Biopharma18 (58)39 (47)28 (67)Academic Medical Centers8 (26)20 (24)7 (17)NIH000NIH and Academic Medical Centers05 (6)2 (5)NIH and Industry02 (2)1 (2)Consortium/foundation02 (2)0Industry and consortium/foundation2 (6)5 (6)2 (5)Academic Medical Centers and consortium/foundation1 (3)2 (2)0Industry, Academic Medical Centers, and consortium/foundation2 (6)2 (2)0Other combinations06 (7)2 (5)[^15]

3.6. Biomarkers {#sec3.6}
---------------

[Table 5](#tbl5){ref-type="table"} shows the biomarkers used as outcome measures in current phase 2 and phase 3 AD clinical trials as described in the federal website; not all trial descriptions in [clinicaltrials.gov](http://clinicaltrials.gov){#intref0060} note if biomarkers are included in the trial.Table 5Biomarkers as outcome measures in phase 2 and phase 3 trials for agents in the Alzheimer\'s disease drug development pipeline ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0915} as of February 12, 2019)BiomarkerN of trials (%)Phase 3Phase 2CSF amyloid14 (33)15 (18)CSF tau13 (31)17 (20)FDG-PET1 (2)10 (12)vMRI10 (24)8 (10)Plasma amyloid5 (12)5 (6)Plasma tau2 (5)1 (1)Amyloid PET11 (26)6 (7)Tau PET8 (19)2 (2)[^16]

AD biomarkers served as secondary outcome measures in 16 phase 3 DMT trials and 29 phase 2 DMT trials. The most common biomarkers used were cerebrospinal fluid (CSF) amyloid, CSF tau, volumetric magnetic resonance imaging, and amyloid PET. Of the 25 phase 3 DMT trials, five trials (20%) used amyloid PET as an entry criterion, two (8%) used CSF amyloid, and eight (32%) used either amyloid PET or CSF amyloid. Ten (17%) out of 60 phase 2 DMT trials used amyloid PET as an entry criterion, seven (12%) used CSF amyloid, and six (10%) used either amyloid PET or CSF amyloid. Ten DMT trials in phase 3 and 37 in phase 2 did not require biomarker confirmation of AD for trial entry.

[Table 5](#tbl5){ref-type="table"}. Biomarkers as outcome measures in phase 2 and phase 3 trials for agents in the Alzheimer\'s disease drug development pipeline ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0065} as of February 12, 2019)

3.7. Devices {#sec3.7}
------------

A variety of approaches to brain stimulation are under study in clinical trials for AD ([Table 6](#tbl6){ref-type="table"}). These range from deep brain stimulation with implanted electrodes to surface application of light, electric current, and laser therapy. Most of the trials target cognitive enhancement; a few trials posit effects on amyloid, tau, inflammation, oxidative stress, or mitochondrial function [@bib20], [@bib21]. Targets have varied from deep brain stimulation of fornix and memory-related structures to surface stimulation of parieto-frontal regions. The few completed studies have shown no consistent cognitive benefit; the techniques have been safe with acceptable adverse event profiles [@bib22]. There are no FDA-defined phases for device trials, and most trials did not list the phase on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0070}. The stages of development for device studies can be divided into pilot, pivotal, and postapproval phases.Table 6Devices in clinical trials for treatment of Alzheimer\'s disease (as of February 12, 2019)DeviceMechanism of actionClinicaltrials.gov IDSponsortDCSLow intensity electric current to modulate cortical excitability and brain plasticity[NCT02772185](NCT02772185){#intref0920}Federal University of Paraiba, Brazil[NCT03638284](NCT03638284){#intref0925}Center for Addiction and Mental Health[NCT03288363](NCT03288363){#intref0930}Centre Hospitalier Esquirol[NCT02873546](NCT02873546){#intref0935}Centre Hospitalier Universitaire de Besancon[NCT02155946](NCT02155946){#intref0940}VA Office of Research and DevelopmentTranscranial alternating current stimulation (tACS)Gamma frequency stimulation to the region of maximum amyloid burden; microglia activation and decrease amyloid and tau depositions[NCT03290326](NCT03290326){#intref0945},\
[NCT03412604](NCT03412604){#intref0950}Beth Israel Deaconess Medical CenterSonoCloudLow intensity contact ultrasound implant to open the blood-brain barrier; allows increased intracerebral bioavailability of anti-AD drugs; may also allow endogenous antibodies to penetrate the brain parenchyma and target amyloid plaques even without any adjunct antiamyloid treatment[NCT03119961](NCT03119961){#intref0955}CarTheraMemorEM 1000Transcranial electromagnetic treatment; disaggregation of toxic oligomers; mitochondrial enhancement[NCT02958930](NCT02958930){#intref0960}NeuroEm TherapeuticsNeuro GammaPhotobiomodulation--administers low energy, near-infrared LED light to the brain transcranially and intranasally; reduces oxidative stress and neuroinflammation[NCT03484143](NCT03484143){#intref0965},\
[NCT03328195](NCT03328195){#intref0970}Vielight[NCT03160027](NCT03160027){#intref0975},\
[NCT03405662](NCT03405662){#intref0980}University of California, San FranciscoRGn530Photobiomodulation device; reduces oxidative stress and neuroinflammation[NCT03672474](NCT03672474){#intref0985}University Hospital, Montpellier (device by REGEnLIFE)Electroconvulsive therapyImprove cognition by increasing brain-derived neurotrophic factor levels[NCT02438202](NCT02438202){#intref0990}Central Institute of Mental Health, MannheimExAblate Model 4000Blood-brain barrier disruption by focal ultrasound[NCT03671889](NCT03671889){#intref0995},\
[NCT03739905](NCT03739905){#intref1000}InSightecGammaSense stimulation systemVisual sensory stimulation device flickering lights at gamma frequency to drive gamma oscillations in brain areas; increase cerebral blood flow and reduce amyloid[NCT03556280](NCT03556280){#intref1005}Cognito Therapeutics[NCT03543878](NCT03543878){#intref1010}Emory University, Georgia Institute of TechnologyLow level laser therapyModulate cellular metabolism and regeneration[NCT02537626](NCT02537626){#intref1015}Erchonia CorporationDBSDirectly target and modulate the activity of brain structures implicated in memory functioning; improve cognition[NCT03347084](NCT03347084){#intref1020}University of California, Los Angeles[NCT03352739](NCT03352739){#intref1025}Xuanwu Hospital, China, Beijing Pins Medical Co.[NCT03622905](NCT03622905){#intref1030}Functional Neuromodulation[NCT03290274](NCT03290274){#intref1035}Hospital San Carlos, MadridrTMSStimulate different areas of the brain to induce changes in brain activity and modify impaired neural networks[NCT03121066](NCT03121066){#intref1040}Universitat Oberta de Catalunya[NCT02908815](NCT02908815){#intref1045}University of Manitoba[NCT03270137](NCT03270137){#intref1050}Instituto Nacional de Psipquiatria Dr. Ramon de la Fuente[NCT02190084](NCT02190084){#intref1055}Central Arkansas Veterans Healthcare System[NCT03778151](NCT03778151){#intref1060}Fondazione Santa LuciaNEUROLITHTPS consisting of short acoustic pulses with an ultrasound frequency to stimulate the brain; maintains and improves cognitive abilities[NCT03770182](NCT03770182){#intref1065}Storz MedicaltVNSStimulation of the auricular branch with electrodes on the external ear to improve cognition[NCT03359902](NCT03359902){#intref1070}University of Florida, NIANeuroADCombination of TMS and cognitive training; stimulates areas of the brain responsible for cognitive functions that have been impaired by AD and makes them more receptive to cognitive training[NCT01825330](NCT01825330){#intref1075}Neuronix[^17][^18]

4. Discussion {#sec4}
=============

In 2018, the FDA approved 59 novel pharmacotherapies across all therapeutic areas, breaking the 1996 record of 53 drug approvals [@bib23], [@bib24]. There were 42 small molecule therapies and 17 biological therapies approved [@bib24]. Eight new neurological drugs were included among the new therapies: 3 migraine treatments (all were calcitonin gene-related peptide receptor antibodies), 2 for seizures in Dravet syndrome (1 included Dravet syndrome and Lennox-Gastaut syndrome), two for hereditary transthyretin-mediated amyloidosis, and 1 for Fabry disease. The latter three agents can be regarded as DMTs, the others provide relief of symptoms albeit life-threatening symptoms in the case of the epilepsies. The therapies for transthyretin-mediated amyloidosis are RNA-based interventions (antisense oligonucleotide or interference RNA) representing a new approach to neurological disorders. Oligonucleotide-based therapies have shown initial promise in Huntington\'s disease and may have applications in other neurodegenerative disorders including AD [@bib25]. There is one RNA-based treatment in the AD pipeline (IONIS MAPTRx).

Several agents have completed clinical trials since the time of last year\'s pipeline analysis and shown no drug-placebo difference. LTMX targeted tau pathology in AD and did not establish efficacy [@bib19]. Azeliragon is a receptor for advanced glycation end products inhibitor and was found to produce no drug-placebo difference in a trial of mild-to-moderate AD. Crenezumab is a monoclonal antibody that targeted oligomeric forms of amyloid-beta protein (Aβ) [@bib26]. It failed to show a drug-placebo difference at the time of a futility analysis in two large clinical trials, and development of the agent was halted. Similarly, aducanumab trials were recently stopped after a futility analysis. Verubecestat is a BACE inhibitor whose development was halted for futility in a mild-to-moderate AD clinical trial [@bib27]. A trial of verubecestat in patients with prodromal AD defined by clinical and amyloid PET measures was halted after a futility analysis suggested that the agent could not succeed. Similarly, lanabecestat did not meet the criteria to continue after a futility analysis. Atabecestat is a BACE inhibitor being assessed in preclinical AD; the trial was discontinued when elevated liver enzymes were observed among some trial participants. Intranasal insulin was assessed in mild-to-moderate AD and showed no drug-placebo difference [@bib28]. Pioglitazone, an insulin sensitizing agent was stopped for futility in a preclinical AD trial. A trial of a FYN inhibitor (AZD0530) used fluorodeoxyglucose PET as the primary outcome and showed no drug-placebo difference on the biomarker or any clinical measure [@bib29]. Fluorodeoxyglucose PET performed well in this multisite trial suggesting it can be used in multicenter trials to show drug-placebo differences with agents that affect brain metabolism. ITI-007 is a multitransmitter agent being developed for the treatment of schizophrenia and was tested in a clinical trial to determine its effect on agitation in AD. No drug-placebo difference was observed in the trial. Of the 17 phase 3 DMTs listed in our 2018 review, eight have been terminated.

GV-971 is a multitargeted molecule that completed a phase 3 clinical trial in China in 2018 [@bib30]. GV-971 has nonclinical evidence of effects on neuroinflammation, amyloid plaques, neurofibrillary tangles, mitochondrial function, and cholinergic function [@bib30]. In a phase 3 trial conducted in China by an international contract research organization, GV-971 showed a statistically significant benefit over placebo on the Alzheimer\'s Disease Assessment Scale--cognitive subscale [@bib31]; a trend toward improvement was noted on the clinical interview-based impression of change [@bib32]. There was no impact on functional and behavioral measures. The outcomes appear to have met the criteria required for approval by the Chinese FDA, and the agent is under review.

Biomarkers play an increasingly important role in AD drug development. Participant selection, target engagement, disease course prediction, evidence of disease modification, and side effect monitoring all involve biomarkers [@bib33]. The NIA--Alzheimer\'s Association established the biomarker-based ATN framework for the diagnosis and characterization of AD [@bib7]. This framework will assist in trials with both accurate diagnosis of AD and biological staging of AD relevant to matching the trial population to the MOA of the agent being assessed [@bib8]. Of the disease-modifying trials currently in the AD pipeline, 52 use amyloid imaging and/or CSF to support the diagnosis, 20 have amyloid imaging as an outcome, ten have tau imaging as an outcome of the intervention. In addition to the specific biomarkers included in the ATN framework, evidence is accruing that the plasma amyloid 40/42 ratio corresponds to the presence of cerebral amyloidosis [@bib34] and that plasma neurofilament light is indicative of neurodegeneration [@bib35]. These increasingly available biomarkers will facilitate screening for clinical trials and may have a role in course prediction and assessing treatment outcome.

Design innovations are evident in recent trials of AD therapeutics. Futility analyses were used to terminate development programs for pioglitazone, verubecestat [@bib27], crenezumab, ITI-007, LY3314814 (lanabecestat), and aducanumab. Futility analyses are conducted when the trial is incomplete but when sufficient data are available to predict if continuing the trial could meet prespecified criteria [@bib36].

The Alzheimer\'s Disease Composite Score (ADCOMS) [@bib37] has been introduced as a cognitive outcome in several development programs including BAN2401, elenbecestat, and xanamem. The ADCOMS is an analytic approach whose score is based on combining scores on items derived from the Alzheimer\'s Disease Assessment Scale--cognitive subscale, clinical dementia rating, and Mini-Mental State Examination [@bib38] after these tools are administered in the standard way. ADCOMS constituents were derived from trials of patients with MCI that showed the most change over a one-year period to develop a score that is most likely to show a drug-placebo difference in trials of patients with early-stage disease and very limited cognitive deficits.

Bayesian adaptive designs are being implemented in AD trials. These have been used broadly in non-AD trials including development of cancer and diabetes therapies [@bib39], [@bib40]. Adaptive trials are being used in the BAN2401 trial, Dominantly Inherited Alzheimer Network--Treatment Unit [@bib41], European Prevention of Alzheimer Disease initiative [@bib42], and the Intranasal Oxytocin for Fronto-temporal Dementia (FOXY) trial of intranasal oxytocin for frontotemporal dementia [@bib43]. The trial of ABT-089 pioneered the use of an adaptive design in AD [@bib44]. Bayesian designs use data derived from the ongoing trial to inform dose allocation, trial duration, sample size, or response to adverse events; decisions are prespecified before trial initiation. Dose-adaptive designs are participant-centric in that they allow study subjects to be assigned to the doses most likely to succeed or least likely to produce adverse events.

It has been argued that there is no "pipeline" of drug development because agents often do not proceed systematically from phase 1 to phase 3 and irregularities are common [@bib45]. We use the word "pipeline" to categorize agents in early, middle, and late-stage trials. In AD drug development, agents tend to proceed from phase 1 single and multiple ascending dose studies to phase 2 proof-of-concept (POC) studies, and then to phase 3 registration-type trials. Testing for POC in phase 2 depends on dose ranges and safety established in phase 1 and provides the foundation for phase 3. Repurposed agents may have irregular pathways going from approved status for one indication to phase 1 or phase 2 to define dose and POC before testing in phase 3 for the AD indication [@bib46], [@bib47]. The concept of "pipeline" applies as an imprecise but generally accurate overview of drug development for AD.

There are more agents in the AD pipeline in 2019 than was observed in the 2018 pipeline. There are 28 agents in phase 3 (compared with 26 in 2018), 74 agents in phase 2 (compared with 63 in 2018), and 30 in phase 1 (compared with 23 in 2018).

The lack of success in AD drug development has given rise to nihilism with regard to the ability of the field to develop agents that meaningfully modify the progression of AD. Suggestions to abandon the amyloid hypothesis, focus exclusively to combination therapies, place more emphasis on lifestyle interventions to prevent AD or reassess our assumptions and build new models to drive drug development are all voiced, and each of these perspectives have merit. Reviews of the pipeline show that lessons are learned from all trials; even negative and futile outcomes are highly informative and provide guidance for future trials. The overview of trials document a shift toward more diversification of targets between phase 3 and phase 2, the entry of combination therapies into the pipeline, and the use of biomarkers to allow early assessments of the impact of candidate interventions on disease biology.

Several agents have shown no drug-placebo difference, and the development programs have been discontinued. A few programs successfully demonstrated drug-placebo differences in phase 2 and are advancing. Progress depends on innovation and learning from exploration of new targets, assessment of new candidates, and implementation of new trial features. As in other chronic disease such as cancer, human immunodeficiency virus (HIV), and cardiovascular disease, a learning phase preceded periods whose sequential incremental successes led to meaningful treatments.Research in context1.Systematic review: There is a high rate of failure of drug development for Alzheimer\'s disease. New treatments are urgently needed, and review of the drug development pipeline can improve our understanding of how best to advance new therapies. We reviewed all drugs currently in clinical trials for Alzheimer\'s disease listed in the federal government database [clinicaltrials.gov](http://clinicaltrials.gov){#intref0075}.2.Interpretation: We showed that there are 132 agents in clinical trials for the treatment for Alzheimer\'s disease. Ninety-six of these drugs are disease-modifying agents intended to change the underlying biology of Alzheimer\'s disease. Nineteen of the drugs are intended to be cognitive enhancing agents, and 14 are being developed for the treatment of neuropsychiatric and behavioral symptoms. We provide an overview of drugs currently in clinical trials for Alzheimer\'s disease.3.Future directions: Progress is being made in terms of defining new targets for the treatment of Alzheimer\'s disease, developing new agents, introducing innovative clinical trial designs, incorporating a broader range of populations in clinical trials, and developing new biomarkers that provide insight into the impact of emerging therapies. Improvements in drug development success rates are anticipated.
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[^1]: Abbreviations: ATRI, Alzheimer\'s Therapeutic Research Institute; BACE, beta-site amyloid precursor protein cleaving enzyme; DMT, disease-modifying therapy; EPA, eicosapentaenoic acid; GABA, gamma-aminobutyric acid; GSK, glycogen synthase kinase; NIA, National Institute on Aging; SV2A, synaptic vesicle protein 2A.

[^2]: NOTE. Twenty-eight agents in 42 phase 3 clinical trials currently ongoing as of February 12, 2019 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0290}.

[^3]: Bolded terms represent new agents into the 2019 phase 3 pipeline.

[^4]: Reported as terminated or completed after the data collection date of February 12, 2019.

[^5]: Phase 2/3 trials.

[^6]: Abbreviations: ABCC1, ATP binding cassette subfamily C member 1; ADCS, Alzheimer\'s Disease Cooperative Study; ADDF, Alzheimer\'s Drug Discovery Foundation; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APOE, apolipoprotein E; APP, amyloid precursor protein; ATRI, Alzheimer\'s Therapeutic Research Institute; BACE, beta-site amyloid precursor protein cleaving enzyme; cAMP, cycling adenosine monophosphate; CB, cannabinoid; DHA, docosahexaenoic acid; DMT, disease-modifying therapy; FLNA, Filamin A; GM-CSF, granulocyte-macrophage colony-stimulating factor; GSK, glycogen synthase kinase; HSD, hydroxysteroid dehydrogenase; HT, hydroxytriptamine; hUCB-MSCs, human umbilical cord blood derived mesenchymal stem cells; MAPK, mitogen-activated protein kinase; MAPT, microtubule-associated tau; NCCIH, National Center for Complementary and Integrative Health; NIA, National Institute on Aging; NMDA, N-methyl-D-aspartate; PDE, phosphodiesterase; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; SGLT2, sodium-glucose transporter 2; SV2A, synaptic vesicle protein 2A; TEP, thiethylperazine.

[^7]: NOTE. Seventy-four agents in 83 phase 2 clinical trials currently ongoing as of February 12, 2019 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0740}.

[^8]: Bolded terms represent new agents into the 2019 phase 2 pipeline.

[^9]: Reported as terminated or completed after the data collection date of February 12, 2019.

[^10]: Phase 1/2 trials.

[^11]: Abbreviations: ADDF, Alzheimer\'s Drug Discovery Foundation; ApoE, apolipoprotein E; BACE, beta-site amyloid precursor protein cleaving enzyme; CSF, cerebrospinal fluid; DMT, disease-modifying therapy; GABA, gamma-aminobutyric acid; GAIM, general amyloid interaction motif; NIA, National Institute on Aging; PPAR, peroxisome proliferator-activated receptor; RIPK1, receptor-interacting serine/threonine-protein kinase 1; SIGLEC-3, sialic acid-binding Ig-like lectin 3; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TREM2, triggering receptor expressed on myeloid cells 2.

[^12]: NOTE. Thirty agents in 31 phase 1 clinical trials currently ongoing as of February 12, 2019 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0905}.

[^13]: Bolded terms represent new agents into the 2019 phase 1 pipeline.

[^14]: Reported as terminated or completed after the data collection date of February 12, 2019.

[^15]: Abbreviation: NIH, National Institutes of Health.

[^16]: Abbreviations: CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; PET, positron emission tomography; vMRI, volumetric magnetic resonance imaging.

[^17]: Abbreviations: AD, Alzheimer\'s disease; DBS, deep brain stimulation; rTMS, repetitive transcranial magnetic stimulation; tDCS, Transcranial direct current stimulation; tACS, Transcranial alternating current stimulation; TMS, transcranial magnetic stimulation; TPS, Transcranial pulse stimulation; tVNS, Transcutaneous vagal nerve stimulation

[^18]: NOTE: Thirty-three device trials currently ongoing ("recruiting," "active, not recruiting," and "not yet recruiting") as of February 12, 2019 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref1080}.
